Rigel Pharmaceuticals Announces Board and Compensation Changes

Ticker: RIGL · Form: 8-K · Filed: May 23, 2025 · CIK: 1034842

Rigel Pharmaceuticals Inc 8-K Filing Summary
FieldDetail
CompanyRigel Pharmaceuticals Inc (RIGL)
Form Type8-K
Filed DateMay 23, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: governance, executive-compensation, board-changes

TL;DR

Rigel shakes up board and exec pay - new faces, new rules.

AI Summary

Rigel Pharmaceuticals, Inc. announced on May 22, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory plans.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Board and executive changes can introduce uncertainty regarding strategic direction and operational stability.

Key Players & Entities

  • Rigel Pharmaceuticals, Inc. (company) — Registrant
  • May 22, 2025 (date) — Date of earliest event reported
  • 611 Gateway Boulevard, Suite 900 (location) — Principal executive offices address
  • South San Francisco, CA (location) — Principal executive offices city and state
  • 94080 (location) — Principal executive offices zip code

FAQ

What specific roles have seen departures or appointments?

The filing indicates the departure of certain officers and directors, and the election of new directors, but does not specify the exact roles affected in this excerpt.

When was the earliest event reported in this filing?

The earliest event reported was on May 22, 2025.

What is the principal executive office address for Rigel Pharmaceuticals?

The principal executive offices are located at 611 Gateway Boulevard, Suite 900, South San Francisco, CA 94080.

What is the company's state of incorporation?

Rigel Pharmaceuticals, Inc. is incorporated in Delaware.

What are the main items covered by this 8-K filing?

This 8-K filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements of certain officers, and submission of matters to a vote of security holders.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 23, 2025 regarding RIGEL PHARMACEUTICALS INC (RIGL).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.